Claims for Patent: 7,968,085

Summary for Patent: 7,968,085

Title:	Hydrogel formulations
Abstract:	A polymeric prodrug composition including a hydrogel, a biologically active moiety and a reversible prodrug linker. The prodrug linker covalently links the hydrogel and the biologically active moiety at a position and the hydrogel has a plurality of pores with openings on its surface. The diameter of the pores is larger than that of the biologically active moiety at least at all points of the pore between at least one of the openings and the position of the biologically active moiety.
Inventor(s):	Hersel; Ulrich (Heidelberg/Hanschuhsheim, DE), Rau; Harald (Heidelberg, DE), Schnepf; Robert (Heidelberg/Dossenheim, DE), Vetter; Dirk (Heidelberg/Neuenheim, DE), Wegge; Thomas (Heidelberg/Ziegelhausen, DE)
Assignee:	Ascendis Pharma A/S (DK)
Application Number:	10/960,851
Patent Claims:	1. A method for the manufacture of a mesoporous hydrogel-biologically active moiety conjugate, comprising: synthesizing the mesoporous hydrogel; and after completing all said synthesizing covalently connecting a prodrug linker to the mesoporous hydrogel; and conjugating a biologically active moiety to the prodrug linker; wherein the connecting and the conjugating can be carried out in either order. 2. The method of claim 1, wherein the prodrug linker has two functional groups, a first one of the two functional groups being complementary to a functional group attached to the mesoporous hydrogel and a second one of the two functional groups being conjugable to the biologically active moiety. 3. The method of claim 2, wherein the first one of the two functional groups is selected from the group of functional groups consisting of carboxylic acid, amino, maleimide, thiol, sulfonic acid, carbonate, carbamate, hydroxyl, aldehyde, ketone, hydrazine, isocyanate, isothiocyanate, phosphoric acid, phosphonic acid, haloacetyl, alkyl halides, acryloyl, alpha-beta unsaturated michael acceptors, arylating agents, aryl fluorides, hydroxylamine, disulfides, vinyl sulfone, vinyl ketone, diazoalkanes, diazoacetyl compounds, epoxide, oxirane, and aziridine. 4. The method of claim 2, wherein the first one of the two functional groups is selected from the group of functional groups consisting of thiol, maleimide, amino, carboxylic acid, carbonate, carbamate, aldehyde, and haloacetyl. 5. The method of claim 2, wherein the second one of the two functional groups is selected from the group of functional groups consisting of carboxylic acid, carbonate, hydroxyl, hydrazine, hydroxylamine, maleamic acid, ketone, amino, aldehyde, thiol and disulfide groups. 6. The method of claim 2, wherein the biologically active moiety has a moiety functional group complimentary to the second one of the two functional groups. 7. The method of claim 6, wherein the moiety functional group is selected from the group of functional groups consisting of thiol, carboxylic acid, amino, hydroxyl, ketone and imidazole. 8. The method of claim 1, wherein the biologically active moiety is a biopolymer. 9. The method of claim 1, wherein the biologically active moiety is selected from the group of proteins or polypeptides consisting of ACTH, adenosine deaminase, agalsidase, albumin, alfa-1 antitrypsin (AAT), alfa-1 proteinase inhibitor (API), alteplase, anistreplase, ancrod serine protease, antibodies (monoclonal or polyclonal, and fragments or fusions), antithrombin III, antitrypsins, aprotinin, asparaginases, biphalin, bone-morphogenic proteins, calcitonin (salmon), collagenase, DNase, endorphins, enfuvirtide, enkephalins, erythropoietins, factor VIIa, factor VIII, factor VIIIa, factor IX, fibrinolysin, fusion proteins, follicle-stimulating hormones, granulocyte colony stimulating factor (G-CSF), galactosidase, glucagon, glucocerebrosidase, granulocyte macrophage colony stimulating factor (GM-CSF), phospholipase-activating protein (PLAP), gonadotropin chorionic (hCG), hemoglobins, hepatitis B vaccines, hirudin, hyaluronidases, idurnonidase, immune globulins, influenza vaccines, interleukins (1 alfa, 1 beta, 2, 3, 4, 6, 10, 11, 12), IL-1 receptor antagonist (rhIL-1ra), insulins, interferons (alfa 2a, alfa 2b, alfa 2c, beta 1a, beta 1b, gamma 1a, gamma 1b), keratinocyte growth factor (KGF), transforming growth factors, lactase, leuprolide, levothyroxine, luteinizing hormone, lyme vaccine, natriuretic peptide, pancrelipase, papain, parathyroid hormone, PDGF, pepsin, platelet activating factor acetylhydrolase (PAF-AH), prolactin, protein C, octreotide, secretin, sermorelin, superoxide dismutase (SOD), somatropins (growth hormone), somatostatin, streptokinase, sucrase, tetanus toxin fragment, tilactase, thrombins, thymosin, thyroid stimulating hormone, thyrotropin, tumor necrosis factor (TNF), TNF receptor-IgG Fc, tissue plasminogen activator (tPA), TSH, urate oxidase, urokinase, vaccines, and plant proteins such as lectins and ricins. 10. The method of claim 1, wherein the biologically active moiety is insulin. 11. The method of claim 1, wherein the hydrogel is functionalized with a functional group selected from the group of reactive functional groups consisting of carboxylic acid, amino, maleimide, thiol, sulfonic acid, carbonate, carbamate, hydroxyl, aldehyde, ketone, hydrazine, isocyanate, isothiocyanate, phosphoric acid, phosphonic acid, haloacetyl, alkyl halides, acryloyl and other alpha-beta unsaturated michael acceptors, arylating agents like aryl fluorides, hydroxylamine, disulfides like pyridyl disulfide, vinyl sulfone, vinyl ketone, diazoalkanes, diazoacetyl compounds, epoxide, oxirane, and aziridine. 12. The method of claim 1, wherein the hydrogel is functionalized with a functional group selected from the group of functional groups consisting of thiol, maleimide, amino, carboxylic acid, carbonate, carbamate, aldehyde, and haloacetyl. 13. The method of claim 1, wherein the prodrug linker is attached to a non-degradable backbone of the mesoporous hydrogel. 14. The method of claim 13 wherein crosslinkers of the mesoporous hydrogel further comprise biodegradable bonds selected from the group of chemically-cleavable bonds consisting of phosphate, phosphonate, carbonate, carbamate, disulfide and ester bonds. 15. The method of claim 1, wherein the mesoporous hydrogel further comprises biodegradable bonds that are enzymatically cleavable. 16. The method of claim 1, wherein the synthesizing the mesoporous hydrogel comprises a condensation reaction.

Details for Patent 7,968,085

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	01/15/1974		2024-07-05
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	12/27/1984		2024-07-05
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	02/15/1985		2024-07-05
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	02/16/1990		2024-07-05
Bel-mar Laboratories, Inc.	CHORIONIC GONADOTROPIN	chorionic gonadotropin	Injection	017054	03/26/1974		2024-07-05